FGFR2 translocations, which are present in 5–38% of ICCs, represent driver mutations and predict tumor sensitivity to specific FGFR inhibitors in cholangiocarcinoma8–10,15–19,21. The gene discussed is FGFR2; the disease is neoplasm.